Allogeneic Mesenchymal Stem Cells After In Vivo Transplantation: A Review.
Derek B AssersonPublished in: Cellular reprogramming (2023)
Autologous mesenchymal stem cells (MSCs) are ideal for tissue regeneration because of their ability to circumvent host rejection, but their procurement and processing present logistical and time-sensitive challenges. Allogeneic MSCs provide an alternative cell-based therapy capable of positively affecting all human organ systems, and can be readily available. Extensive research has been conducted in the treatment of autoimmune, degenerative, and inflammatory diseases with such stem cells, and has demonstrated predominantly safe outcomes with minimal complications. Nevertheless, continued clinical trials are necessary to ascertain optimal harvest and transplant techniques.
Keyphrases
- mesenchymal stem cells
- cell therapy
- bone marrow
- stem cells
- umbilical cord
- stem cell transplantation
- clinical trial
- endothelial cells
- hematopoietic stem cell
- high dose
- oxidative stress
- multiple sclerosis
- single cell
- risk factors
- pluripotent stem cells
- induced pluripotent stem cells
- skeletal muscle
- african american
- adipose tissue
- metabolic syndrome
- drug induced
- phase ii
- study protocol